Quality of life after cancer—How the extent of impairment is influenced by patient characteristics

Peters, Elisabeth; Mendoza Schulz, Laura; Reuss-Borst, Monika

doi:10.1186/s12885-016-2822-z

BMC Cancer

Table 6 Depicts statistically and clinically significant differences in scale values between groups of patients with different malignancies

From: Quality of life after cancer—How the extent of impairment is influenced by patient characteristics

Score	Diagnosis	N	M ± SD	P value	Difference
PF	Breast cancer	824	66.95 ± 19.58	.035	5.35
PF	Malignancies of female genital organs	174	61.30 ± 20.26	.035	5.35
PF	Breast cancer	824	66.95 ± 19.58	.033	7.87
PF	Prostate carcinoma	85	74.82 ± 20.12	.033	7.87
PF	Malignancies of female genital organs	174	61.30 ± 20.26	.000	13.52
PF	Prostate carcinoma	85	74.82 ± 20.12	.000	13.52
EF	Colorectal carcinoma	211	55.92 ± 28.83	.032	7.09
EF	Breast carcinoma	801	48.28 ± 28.37	.032	7.09
EF	Colorectal carcinoma	211	55.92 ± 28.83	.002	18.34
EF	Malignancies of thyroid and other endocrine glands	55	37.58 ± 26.88	.002	18.34
EF	Prostate carcinoma	84	58.73 ± 29.71	.002	21.15
EF	Malignancies of thyroid and other endocrine glands	55	37.58 ± 26.88	.002	21.15
EF	Hemoblastoses	234	52.03 ± 29.91	.015	14.45
EF	Malignancies of thyroid and other endocrine glands	55	37.58 ± 26.88	.015	14.45
EF	gastrointestinal carcinoma	93	54.39 ± 29.09	.019	16.81
EF	Malignancies of thyroid and other endocrine glands	55	37.58 ± 26.88	.019	16.81
CF	Colorectal carcinoma	216	71.45 ± 27.28	.006	8.96
CF	Breast cancer	826	62.49 ± 30.19	.006	8.96
SF	Malignancies of female genital organs	170	51.57 ± 33.00	.039	14.14
SF	Prostate carcinoma	87	65.71 ± 29.24	.039	14.14
RF	Breast cancer	820	51.10 ± 29.56	.044	11.35
RF	Prostate carcinoma	87	62.45 ± 31.15	.044	11.35
RF	Malignancies of female genital organs	168	48.12 ± 31.61	.025	14.33
RF	Prostate carcinoma	87	62.45 ± 31.15	.025	14.33
F	Breast cancer	822	57.88 ± 26.77	.005	13.31
F	Prostate carcinoma	87	44.57 ± 28.73	.005	13.31
F	Malignancies of female genital organs	169	59.17 ± 25.96	.007	14.60
F	Prostate carcinoma	87	44.57 ± 28.73	.007	14.60
F	Prostate carcinoma	87	44.57 ± 28.73	.008	14.19
F	Hämoblastosen	239	58.76 ± 27.83	.008	14.19
F	Prostate carcinoma	239	44.57 ± 28.73	.017	15.50
F	gastrointestinal carcinoma	91	60.07 ± 27.67	.017	15.50

Abbreviations: PF physical functioning, EF emotional functioning, CF cognitive functioning, SF social functioning, RF role functioning, F fatigue

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com